|
Photo placeholder
|
| Affiliations |
University of California, San Francisco |
| Country |
USA |
| H-index |
200 |
| ORCID |
0000-0002-2777-8648 |
| Research Focus |
[Alzheimer's Disease](/diseases/alzheimers), Neuroimaging, Biomarkers |
| Mechanisms |
MRI, PET imaging, Biomarkers, Prevention trials |
Michael W. Weiner is a pioneering researcher in the use of neuroimaging and biomarkers for Alzheimer's disease diagnosis and tracking. As director of the Alzheimer's Disease Neuroimaging Initiative (ADNI) and leader of numerous large-scale multi-site studies, Dr. Weiner has transformed how Alzheimer's disease is diagnosed and monitored in clinical practice and research.1
Dr. Weiner completed his medical training and radiology residency at UCSF, where he also pursued research training in nuclear medicine and neuroimaging. He has been a professor at UCSF since 1985, where he founded and directs the Center for Imaging of Neurodegenerative Diseases (CIND). He has led ADNI since its inception in 2004, coordinating over 50 sites across North America and Europe.1,2
Dr. Weiner's research has revolutionized Alzheimer's disease diagnosis and monitoring through neuroimaging and biomarkers:
- Established the Alzheimer's Disease Neuroimaging Initiative (ADNI), the largest Alzheimer's imaging study
- Standardized MRI and PET protocols used worldwide for AD research
- Created public databases used by thousands of researchers globally
- MRI: Developed techniques for measuring hippocampal atrophy and white matter changes
- PET: Pioneered amyloid and tau PET imaging for AD diagnosis
- Advanced Methods: Diffusion tensor imaging, functional MRI, and ASL perfusion
- Established cerebrospinal fluid biomarker protocols for AD
- Validated blood-based biomarkers for screening and monitoring
- Integrated biomarker data with imaging for comprehensive patient characterization
- Led neuroimaging components of numerous AD clinical trials
- Developed imaging endpoints for disease-modifying therapies
- Established protocols for monitoring treatment response
- ADNI Foundation: Established the largest AD imaging database
- Standardization: Created worldwide imaging standards for AD research
- Biomarker Validation: Validated CSF and blood biomarkers
- Trial Design: Improved imaging endpoints for clinical trials
- Weiner MW, et al. "The Alzheimer's Disease Neuroimaging Initiative: a review of papers published in 2011-2012." Alzheimers Dement. 2013;9(5):e68-e73. PMID: 23932184
- Weiner MW, et al. "The谁的阿尔茨海默病神经影像学倡议? 2013 update." Alzheimers Dement. 2013;9(4):e61-e66. PMID: 23932183
- Veitch DP, et al. "Alzheimer's Disease Neuroimaging Initiative: 2019 update on recruitment, enrollment, and procedures." Alzheimers Dement. 2019;15(11):1428-1437. PMID: 31659337
- Petersen RC, et al. "Alzheimer's Disease Neuroimaging Initiative: 2014 update." Alzheimers Dement. 2015;11(6):620-629. PMID: 26018436
- Jack CR, et al. "Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers." Lancet Neurol. 2013;12(2):207-216. PMID: 23375564
¶ Awards and Recognition
- MetLife Foundation Award
- American College of Radiology Distinguished Researcher Award
- AAAS Fellow
The study of Michael W. Weiner has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
flowchart LR
subgraph Focus ["Research Focus"]
F1["Michael W. Weiner"]
end
subgraph Contributions ["Key Contributions"]
C1["Mechanistic<br>Discovery"]
C2["Therapeutic<br>Target"]
C3["Biomarker<br>Development"]
end
F1 --> C1
F1 --> C2
F1 --> C3
C1 --> Knowledge["Disease<br>Knowledge"]
C2 --> Knowledge
C3 --> Knowledge